RemovedRisk Factors
protect the privacy of personal information, such as HIPAA, as well as the costs and operational consequences of implementing further data protection measures.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
debarment from government contracts, curtailment of operations in certain jurisdictions, competitive or reputational harm, litigation or regulatory action and other consequences that might adversely affect our results of operations, financial condition or strategic objectives.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedRisk Factors
The global economy has been negatively impacted by the military conflict between Russia and Ukraine. Furthermore, governments in the United States, United Kingdom and European Union have each imposed export controls on certain products and financial and economic sanctions on certain industry sectors and parties in Russia, and Russia has imposed counter-
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedRisk Factors
For Additionally, in connection with our annual assessment for the year ended December 31, 2024, we recognized a non-cash Goodwill impairment charge of $645 $645.0 million ($330 ($315.0 million for the Reconstructive P&R reporting unit and $315 $330.0 million for the Prevention & Recovery Recon reporting unit) as part of our annual Goodwill impairment testing. unit).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Failure to attract, develop, engage, and retain qualified employees, whether as a result of an insufficient number of qualified applicants, difficulty in recruiting new employees, or inadequate resources to train, integrate, and retain qualified employees, could impair our ability to execute our business strategy and could have a material adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The spread or fear of spread of contagious diseases, terrorist activity, man-made or natural disasters, actual or threatened war, political unrest, civil strife and other geopolitical uncertainty could have cause a similar effect on decline in the demand for our products, which may adversely affect our financial condition or our condition, growth strategy. strategy and operating performance.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If future operating performance at either of our reporting units were to fall significantly below current levels, if competing or alternative technologies emerge, if market conditions for an acquired business decline, or if there is a further sustained decrease in our publicly reported stock price and market capitalization, among other things, we could incur, under current applicable accounting rules, additional non-cash charges to operating earnings for Goodwill impairment, which could be material and may adversely affect our reported earnings. earnings and may impact our ability to designate our Swiss-Franc cross-currency swaps as net investment hedges.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
In addition, such breaches in security could result in litigation, regulatory action and potential liability, including liability under federal or state laws that protect the privacy of personal information, such as HIPAA, as well as the costs and operational consequences of implementing further data protection measures.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Risks relating to contagious diseases, terrorist activity, man-made or natural disasters and war could reduce have adversely impacted, and may, either alone or in combination with other risks, in the demand for our products and future have an adverse effect on our results of operations, financial condition, and business.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our business, financial condition and results of operations could be adversely affected by disruptions in the global economy caused by geopolitical uncertainty, political instability, and conflicts, such as the ongoing conflict armed conflicts between Russia and Ukraine. Ukraine and in the Middle East.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
It is also possible that other federal, state or foreign enforcement authorities might take action under other regulatory authority, such as false claims laws or consumer protection laws, if they consider our business activities to constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment of our operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Further escalation of geopolitical tensions related to the military conflict, these armed conflicts, including increased trade barriers or restrictions on global trade, which could affect Russia’s allies and other countries, such as China, could result in, among other things, cyberattacks, additional supply disruptions, lower consumer demand and changes to foreign exchange rates and financial markets, any of which may adversely affect our business and supply chain.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our information technology infrastructure and information are vulnerable to service interruptions, data corruption, cyber-based attacks, or network security breaches, which could result in the disruption of operations or the loss of data confidentiality. breaches.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
For example, the introduction of new tariffs or trade restrictions, such as the tariffs announced by the new U.S. administration in February 2025 restrictions and any retaliatory trade measures could also increase the cost of or impair sourcing flexibility for raw materials and other inputs used in the manufacturing of our products.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any such While to date we have not experienced any material cybersecurity incidents, future attacks and incidents could have a material adverse effect on our business, financial condition, results of operations or liquidity.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
If For example, if the Lima Acquisition is not successfully integrated into our existing operations, our business and financial results may be adversely affected.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
We may elect the one year scope exception provided by the Exchange Act and the applicable SEC rules and regulations concerning business combinations as we did for the Lima acquisition, but we can not cannot avoid the requirements.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Energy, commodity, raw material energy, material, labor and other cost inflation has impacted and could continue to impact our results of operations, financial condition and cash flows.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Changes in international trade policy can also could have a substantial adverse effect on our business, results of operations, financial position and cash flows.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
We complement our organic growth plans with strategic acquisitions and other investments. Acquisitions can significantly affect our reported results, and so we also report the change in our Net sales between periods both from Existing businesses and Acquired businesses. The change in Net sales due to acquisitions for the years ended December 31, 2025 and 2024 presented in this filing represents the incremental sales in comparison to the portion of the prior period during which we did not own the business. Business acquisitions of a distributor may not add incremental sales in Acquired businesses because we may have had existing business sales through the distributor and the acquisition brings the business into Enovis under a direct sales model and reduces operating costs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
On October 7, 2025, we completed the sale of our Dr Comfort Footcare Solutions U.S. operations of our P&R segment to Promus Equity Partners in an asset deal, with an effective date of October 4, 2025 (the “Dr Comfort Divestiture”). The sale includes inventory, machinery and equipment, and intangible assets for consideration of up to $60 million in cash, consisting of an upfront payment of $45 million and up to $15 million payable in the future upon the achievement of certain milestones.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In the year ended December 31, 2025, the Company completed seven transactions for $36.9 million total purchase consideration, including deferred consideration and estimated contingent consideration which included the acquisition of three distributors, two businesses, and two purchases of intellectual property. Of these transactions, three were in the P&R segment and four were in the Recon segment.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
(4) MDR and other costs includes (i) $9.8 million for the year ended December 31, 2025 in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $0.6 million for the year ended December 31, 2025 of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
(5) Strategic transaction costs includes: (i) $39.4 million for the year ended December 31, 2025 related to non-recurring integration costs associated with the Lima Acquisition, which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are nonrecurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $19.5 million for the year ended December 31, 2025 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $1.5 million for the year ended December 31, 2025 related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
(6) Inventory step-up expense represents the incremental expense of inventory sold recognized at its fair value after business combination accounting is applied versus the expense that would have been recognized if sold at its cost to manufacture. Since only the inventory that existed at the business combination date was stepped-up to fair value, we believe excluding the incremental expense enhances comparability between periods, allowing investors to better understand our business performance and the underlying trends relevant to our ongoing business performance.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
(4) MDR and other costs includes (i) $16.0 million for the year ended December 31, 2024 in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $3.5 million for the year ended December 31, 2024 of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
(5) Strategic transaction costs includes: (i) $64.9 million for the year ended December 31, 2024 related to non-recurring integration costs associated with the Lima Acquisition, which includes (a) payroll and retention costs for roles eliminated in connection with the integration of our recent acquisition of Lima where a legal notice period was required prior to the employee’s separation from the Company, or integration-related daily activities not related to former roles performed by an employee during their legal notice period and prior to their separation from the Company. In each case, such costs relate solely to roles eliminated in connection with the integration of the Lima acquisition, and are nonrecurring and not part of our normal business operations; (b) professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters including legal entity consolidation, costs associated with rebranding and marketing acquired business under Enovis name, such as marketing materials, trade show redesign costs and product labeling; and (c) integration related costs associated with sales agent and distributor network rationalization, including contract termination and retention expenses, supply chain and portfolio integration, and quality management system consolidation, (ii) $8.8 million for the year ended December 31, 2024 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $4.6 million for the year ended December 31, 2024 related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
(6) Inventory step-up expense represents the incremental expense of inventory sold recognized at its fair value after business combination accounting is applied versus the expense that would have been recognized if sold at its cost to manufacture. Since only the inventory that existed at the business combination date was stepped-up to fair value, we believe excluding the incremental expense enhances comparability between periods, allowing investors to better understand our business performance and the underlying trends relevant to our ongoing business performance.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
(4) MDR and other costs includes (i) $21.3 million for the year ended December 31, 2023 in non-recurring costs specific to updating our quality system, product labeling, asset write-offs and product remanufacturing to comply with the medical device reporting regulations and other requirements of the new medical device regulations in the European Union for devices which were introduced to the market prior to the regulation and (ii) $6.1 million for the year ended December 31, 2023 of expenses to resolve certain infrequent, non-recurring regulatory or other legal matters. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
(5) Strategic transaction costs includes: (i) $12.2 million for the year ended December 31, 2023 related to transaction costs and non-recurring integration costs associated with the Lima Acquisition, which includes professional and consulting fees specifically incurred to consummate the acquisition and advise and facilitate on post-acquisition integration matters, (ii) $5.5 million for the year ended December 31, 2023 of non-recurring (non-Lima) acquisition integration costs and other costs associated with non-recurring projects, including global ERP rationalization and establishment of a new shared service center, and (iii) $20.6 million for the year ended December 31, 2023 related to the Separation of our former fabrication technology business. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
(6) Inventory step-up expense represents the incremental expense of inventory sold recognized at its fair value after business combination accounting is applied versus the expense that would have been recognized if sold at its cost to manufacture. Since only the inventory that existed at the business combination date was stepped-up to fair value, we believe excluding the incremental expense enhances comparability between periods, allowing investors to better understand our business performance and the underlying trends relevant to our ongoing business performance.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
We complement our organic growth plans with strategic acquisitions and other investments. Acquisitions can significantly affect our reported results, and so we also report the Net sales on a Comparable Sales basis and present a Comparable Sales Growth rate to provide information on the operating performance of the business. Comparable Sales and Comparable Sales Growth rate are defined in the “Non-GAAP Measures” section below.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
During the year ended December 31, 2022, the Company completed two business acquisitions for aggregate net cash consideration of $50.5 million. In the second quarter of 2022, the Company acquired KICo Knee Innovation Company Pty Limited and subsidiaries, an Australian private company doing business as 360 Med Care, which is a medical device distributor that bundles certain computer-assisted surgery and patient experience enhancement programs to add value to the device supply arrangements with surgeons, hospitals, and insurers. In the third quarter of 2022, the Company acquired a controlling interest in Insight Medical Systems, the flagship product of which is the ARVIS surgical navigation system.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Once the Separation was completed in the second quarter of 2022, we began classifying the results from the fabrication technology business for the comparable periods presented as a discontinued operation in our financial statements. Accordingly, the results of our fabrication technology businesses in our financial statements prior to its spin-off as a separate public company are excluded from continuing operations in the accompanying financials for the year ended December 31, 2022.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Please see Part I. Item 1A. “Risk Factors” in this Form 10-K for further discussion of the Company’s risks relating to the Separation.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Comparable Sales adjusts net sales for prior periods to include the sales of acquired businesses prior to our ownership from acquisitions that closed in the periods presented and to exclude the sales of certain non-core product lines that were divested or discontinued, as applicable, during the periods presented. The acquired businesses include Lima, Novastep, and KICo, which are reflected in the Recon segment, and the excluded non-core product lines are comprised of the divested compression hosiery product line in the P&R segment and certain discontinued third-party OEM relationships in the Recon segment. Comparable Sales Growth rate represents the change in Comparable Sales for the current period from Comparable Sales for the prior year period. Comparable Sales and Comparable Sales Growth rate assist our management in evaluating operating performance over time because the impact of significant acquisitions and divestitures or discontinuance of certain non-core product lines subsequent to prior periods may obscure underlying business trends and make the evaluation of period-over-period performance difficult. Comparable Sales and Comparable Sales Growth rate are presented for illustrative purposes only and do not and are not intended to comply with Article 11 of Regulation S-X promulgated by the SEC in respect of proforma financial information, and may differ, including materially, from proforma financial statements presented in accordance therewith.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
(1) Non-operating components of Net loss from continuing operations are not allocated to the segments.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
(1) Non-operating components of Net loss from continuing operations are not allocated to the segments.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
(1) Non-operating components of Net loss from continuing operations are not allocated to the segments.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
(1) Comparable Sales adjusts net sales for prior periods to include the sales of acquired businesses prior to our ownership from acquisitions that closed in the periods presented and to exclude the sales of divested businesses and certain discontinued Recon products lines in conjunction with the Lima Acquisition. The acquired businesses include Lima and Novastep, which are reflected in the Recon segment, and the excluded non-core product lines are comprised of a divested compression hosiery product line in the P&R segment and certain discontinued third-party OEM relationships in the Recon segment.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
(1) Comparable Sales adjusts net sales for prior periods to include the sales of acquired businesses prior to our ownership from acquisitions that closed in the periods presented and to exclude the sales of divested businesses and certain discontinued Recon products lines in conjunction with the Lima Acquisition. The acquired businesses include Lima, Novastep, and KiCo, which are reflected in the Recon segment, and the excluded non-core product lines are comprised of a divested compression hosiery product line in the P&R segment and certain discontinued third-party OEM relationships in the Recon segment.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Interest expense, net decreased by $4.4 million, primarily due to a reduction in debt balances as a result of the Separation-related debt redemptions at the beginning of the second quarter of 2022, the extinguishment of the outstanding balance of our previous term loan in conjunction with the ESAB investment sale, and interest savings from $7.3 million interest received on the Swiss Franc cross-currency swap agreements.
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RemovedMD&A
Net loss from continuing operations increased $15.6 million during 2023 in comparison to 2022, primarily due to one-time income items in the prior year period, including the Unrealized gain on investment in ESAB Corporation, Gain on cost basis investment, Insurance settlement gain, partially offset by the reduction of debt extinguishment charges and the aforementioned net impact of the Gross profit and Selling, general, and administrative increases as well as the decrease in Interest expense, net and the impact of unfavorable discrete tax items in 2022. Adjusted EBITDA increased due to organic growth. Adjusted
Read it in 10-K Feb 26, 2025 at sec.govopen_in_new
RewordedMD&A
Restructuring and other charges (2)(3) 20.9 24.3 45.2 5.2 10.0 15.1 MDR and other costs (3) 10.1 9.4 19.5 (3)(4) 5.7 4.7 10.4 Strategic transaction costs (3) 4.3 74.0 78.3 (3)(5) 9.5 50.8 60.4 Stock-based compensation (3) 18.1 11.6 29.7 18.6 14.7 33.3 Depreciation and other amortization 20.6 96.7 117.3 18.8 101.9 120.7 Amortization of acquired intangibles 92.3 73.2 165.5 91.5 82.1 173.6 Goodwill impairment charge 315.0 330.0 645.0 387.8 662.0 1,049.8 Purchase of royalty interest — 45.8 45.8 Inventory step-up (6) — 51.7 51.7 18.1 18.1 Adjusted EBITDA (non-GAAP) $ 159.6 163.1 $ 216.9 239.9 $ 376.5 403.0 Adjusted EBITDA margin (non-GAAP) 14.5 14.3 % 21.5 21.6 % 17.9 %
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net Operating loss from continuing operations increased $773.6 million during 2024 in comparison to 2023, increased, primarily due to a Goodwill impairment charge of $645.0 $330.0 million, a $65.2 $48.9 million increase in strategic transactions transaction costs from including the deal costs for the Lima Acquisition and integration activities, a $37.4 million increase in interest expense, net, a $32.0 million costs, and an increase in amortization of acquired intangibles, and an increase in depreciation intangibles and inventory fair value step-up amortization charges, partially offset by an increase in Gross Profit from the Lima Acquisition. aforementioned factors driving growth.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Selling, general and administrative expense increased $57.4 by $8.3 million during 2023 in comparison to 2022, over the same period primarily due to increased an increase in commissions driven by higher sales, sales and increases in existing business investments to support growth, spending on MDR and other costs, and cost inflation, partially nearly entirely offset by cost reduction initiatives and a net decrease in Strategic transactions Lima Acquisition integration costs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2024 2025 P&R Recon Total (Dollars in millions) Net loss from continuing operations Loss (GAAP) (1) $ (827.4) (1,183.6) Net Loss margin (GAAP) (52.7) % Loss from discontinued operations, net of taxes 1.9 Income tax expense 4.5 22.3 Other income, expense, net (9.9) 0.4 Interest expense, net 57.1 34.8 Operating loss (GAAP) $ (321.8) (374.1) $ (454.0) (775.7) (750.2) (1,124.2) Operating loss margin (29.3) (32.9) % (45.0) (67.5) % (36.8) (50.0) % Adjusted to add:
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Additionally, Net sales Sales increased during 2023 as compared to 2022 primarily due to an the increase in sales from existing businesses across both of our segments and to segments, partially offset by a lesser extent sales decrease from acquired businesses the divestiture of a hosiery product line in Recon and favorable foreign currency translation. our P&R segment.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Our principal raw materials and components are include foam ethylene vinyl acetate, ethylene-vinyl-acetate copolymer for used in our bracing and vascular products in P&R within P&R, and cobalt chromium alloy, stainless steel cobalt-chromium alloys, stainless-steel alloys, titanium alloy alloys, and ultra high molecular weight ultra-high-molecular-weight polyethylene used in Recon. our Recon products.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, 2025 2024 2023 2022 (Dollars in millions) Net sales $1,111.1 $1,009.7 $630.4 $535.5 Gross profit $731.2 $612.3 $433.2 $351.1 Gross profit margin 65.8% 60.6% 68.7% 65.6% Selling, general and administrative expenses $603.5 $595.2 $387.6 $334.0 Research and development expense $83.3 $55.6 $40.3 $27.4 Amortization of acquired intangibles $82.1 $73.2 $40.0 $46.2 Restructuring and other charges $4.7 $12.3 $6.4 $9.4 Purchase of royalty interest $45.8 $— $— Goodwill impairment charge $662.0 $330.0 $— $— Operating loss (GAAP) $(750.2) $(454.0) $(41.0) $(52.9) Operating loss margin (GAAP) (67.5)% (45.0)% (6.5)% (9.9)% Adjusted EBITDA (non-GAAP) $239.9 $216.9 $116.7 $94.7 Adjusted EBITDA margin (non-GAAP) 21.6% 21.5% 18.5% 17.7%
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Additionally, cash flows used in investing activities in 2025, 2024, 2023, and 2022 2023 include $197.4 million, $180.7 million, and $122.2 million, and $105.5 million, respectively, for purchases of property, plant, equipment, and intangibles. intangibles, which represents overall higher capital investments driven by recent acquisitions, including surgical implant instruments that support sales growth in Recon.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Cash flows provided used by financing activities in 2024 2025 include net debt borrowings paydown of $859.2 $36.9 million, partially offset by debt issuance costs of $6.7 million, amounts paid for common stock repurchases of $4.8 million $3.5 million, and amounts paid for deferred consideration payments on acquisitions of $8.8 $6.6 million.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Net sales in P&R increased $21.2 million, or 2.0%, 2.0% in the year ended December 31, 2024 compared with the prior year period, which was negatively impacted due to solid growth in existing business, partially offset by a $11.1 million decrease from divesting a minor product line. line and unfavorable foreign translation.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
As a result, the Company recognized a non-cash goodwill impairment charge of $645 $540.8 million ($330 in the quarter ended October 3, 2025 ($222.3 million for the P&R reporting unit and $318.6 million for the Reconstructive reporting unit and $315 million for the Prevention & Recovery reporting unit).
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The Following the Amendment, the Term Loan Facility requires required quarterly principal repayments, which is repayments of $5 million each quarter, million, and matures would mature on April 4, 2027 (the “2024 Term Loan”). 2027.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new